Concourse Financial Group Securities, Inc. Akero Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.56 Billion
Q2 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share
Q2 2024 Jul 23, 2024	BUY	$18.31 - $24.62 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$17.76 - $31.18 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$11.38 - $50.33 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$41.19 - $52.25 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$41.19 - $52.25 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$36.89 - $56.88 $0 - $0
Q1 2023 May 15, 2023	BUY	$37.27 - $50.24 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$33.44 - $54.8 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$10.15 - $34.05 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$8.0 - $15.01 $0 - $0
Q1 2022 May 09, 2022	BUY	$12.97 - $22.26 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$19.87 - $26.24 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$18.65 - $25.46 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$24.81 - $32.35 $0 - $0
Q1 2021 May 13, 2021	BUY	$24.04 - $34.19 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$25.12 - $29.89 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$30.79 - $39.92 $0 - $0
Q2 2020 Aug 13, 2020	BUY	$19.25 - $26.76 $0 - $0
Q1 2020 May 13, 2020	BUY	$12.8 - $27.05 $0 - $0
Q4 2019 Feb 14, 2020	BUY	$17.37 - $27.27 $0 - $0
Q3 2019 Nov 13, 2019	BUY	$16.89 - $29.88 $0 - $0
Q2 2019 Aug 13, 2019	BUY	$18.08 - $19.83 $0 - $0

Others Institutions Holding AKRO

# of Institutions

168

Shares Held

72.7M

Call Options Held

178K

Put Options Held

164K

Janus Henderson Group PLC London, X0

6.88M
Shares

$193 Million
0.09% of portfolio
Black Rock Inc. New York, NY

5.59M
Shares

$156 Million
0.0% of portfolio
Rtw Investments, LP New York, NY

5.43M
Shares

$152 Million
2.13% of portfolio
General Atlantic LLC New York, NY

5.23M
Shares

$147 Million
3.88% of portfolio
Wellington Management Group LLP Boston, MA

5.11M
Shares

$143 Million
0.02% of portfolio

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.3B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account